LTIMindtree Announces Partnership and Strategic Investment in Voicing.AI, An Agentic AI Solution for Customer Engagement Processes
4.12.2024 06:00:00 EET | Business Wire | Press release
LTIMindtree USA Inc., a wholly owned subsidiary of LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, announced a partnership, including a strategic investment in Voicing.AI, a next-generation start-up. This partnership aligns with LTIMindtree’s strategy, AI in everything, Everything for AI and AI for Everyone. Voicing.AI’s proprietary technology brings human-like voice capability across more than 20 languages with conversational, contextual, and emotional intelligence, in what is typically referred to as ‘agentic AI’.
LTIMindtree aims to reshape the future of Business Processes by leveraging AI-led platforms. This will enable their clients to optimize costs, reduce risk, enhance user experience, address revenue leakages, and enhance upsell opportunities. LTIMindtree will help clients integrate Voicing.AI with their custom tools, knowledge bases - both structured or unstructured, CRM systems, and leading call management platforms and systems. This Agentic AI technology is fully compliant with SOC2, HIPAA, and multi-layered data security protocols.
You can view the demo video here.
“Our investment with Voicing.AI aims to redefine how businesses interact with their customers through intelligent automation and AI,” said Debashis Chatterjee, CEO and Managing Director, LTIMindtree. “This partnership and investment not only underscore our commitment to innovation but also ensures that LTIMindtree is an early mover in capitalizing on the disruption expected across platform operations.”
“Voicing.AI is fundamentally disrupting the massive customer engagement market by powering new revenue growth, personalizing customer connections, and fostering a human dialogue between a business and its customers. LTIMindtree presented us with a deeply focused comprehensive vision for this Responsible AI transformation and we are excited to partner with them,” said Abhi Kumar, Co-Founder - Voicing.AI. “We look forward to working with LTIMindtree’s global clients to fulfill the growing demand as more enterprises look to automate their platform operations.”
About LTIMindtree:
LTIMindtree is a global technology consulting and digital solutions company that enables enterprises across industries to reimagine business models, accelerate innovation, and maximize growth by harnessing digital technologies. As a digital transformation partner to more than 700 clients, LTIMindtree brings extensive domain and technology expertise to help drive superior competitive differentiation, customer experiences, and business outcomes in a converging world. Powered by 84,000+ talented and entrepreneurial professionals across more than 30 countries, LTIMindtree — a Larsen & Toubro Group company — solves the most complex business challenges and delivers transformation at scale. For more information, please visit https://www.ltimindtree.com/.
About Voicing.AI:
Voicing.AI provides codeless infrastructure for enterprises to build and scale human-like AI voice agents to maximize productivity & business outcomes, with top-tier trust and safety protocols for a Responsible AI. Voicing AI helps enterprises progress with every customer interaction: Sales & Marketing, supercharge your conversion rate by up to 8x by instantly calling inbound leads as soon as they engage with you; Customer Success: enhance your customer care experience by instantly reaching out to customers the moment they request assistance; Listen to Users: improve your feedback collection by instantly reaching out to your users at any interaction. For more information, please visit https://www.voicing.ai/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241203436754/en/
Contacts
Media Contacts:
Michelle Kumar | Global Media Relations | Michelle.NaliniKumar@ltimindtree.com
Gitanjali Sreepal | Global Media Relations | Gitanjali.sreepal@ltimindtree.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom